Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Oncology Shines And Antivirals Recover In Q3

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

The path forward for Gilead Sciences, Inc.’s filgotinib looks increasingly uncertain as the company weighs strategies following a surprise rejection over the summer by the US Food and Drug Administration. During Gilead’s third quarter earnings call, execs announced that the company has hit the brakes on several studies of the autoimmune drug, pending a meeting with the agency next quarter.

But aside from that, the company remains on course with its rapidly expanding oncology ventures, while its traditional antivirals business...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.